Trulicity Injury Lawsuit: What Victims Need to Know

Trulicity (dulaglutide) is a once-weekly GLP-1 drug prescribed to help adults with type 2 diabetes control blood sugar. Since its FDA approval in 2014, patients across the country have filed lawsuits alleging Trulicity triggered conditions such as acute pancreatitis, gallbladder disease, bowel obstruction, and ileus. These are not routine side effects. They are catastrophic injuries that require hospitalization, surgeries, and in many cases, permanent changes to daily life.

At Boesen Law, we have represented clients in dangerous drug cases where manufacturers failed to disclose risks or downplayed the severity of harm. Trulicity litigation is no different: it focuses on whether Eli Lilly provided adequate warnings, and whether patients had the information they needed to make an informed choice before starting treatment.

Trulicity Drug History and FDA Safety Notes

Every dangerous-drug case turns on the paper trail of what the manufacturer knew, when they knew it, and how they disclosed that information to patients and doctors. With Trulicity, the record shows a mix of early warnings and later signals that continue to fuel litigation today.

• FDA approval: Dulaglutide (Trulicity) was first approved in 2014 for adults with type 2 diabetes. From day one, the label carried a boxed warning about thyroid C-cell tumors and contraindications for patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Evolving signals: GLP-1 drugs have always disclosed nausea, vomiting, and diarrhea. But lawsuits emphasize that Eli Lilly did not adequately warn about the risk of acute pancreatitis, gallbladder disease, or ileus, despite adverse-event reports accumulating over time.
• Regulatory oversight: The FDA has also issued broader warnings about compounded or unapproved GLP-1 products being marketed for weight loss, raising further questions about how risks are communicated to patients.
• Current scrutiny: Trulicity is increasingly grouped with Ozempic, Wegovy, and Mounjaro in litigation alleging the manufacturers underplayed the severity of GI and gallbladder injuries.

In Trulicity cases, the alleged delay or insufficiency in updating the label is central to proving a failure-to-warn claim, giving injured patients a stronger argument for holding the drugmaker accountable.

For answers to your questions, call:
(303) 999-9999

Current Lawsuit Landscape and Typical Allegations

The litigation over Trulicity is still developing, but the themes are familiar to anyone following the GLP-1 class. Plaintiffs argue that Eli Lilly failed to adequately warn about the severity of pancreatitis, gallbladder disease, and bowel obstruction. While the drug’s label referenced possible risks, the claims focus on whether those warnings were strong enough, prominent enough, and updated quickly enough as adverse events piled up.

These lawsuits rely heavily on objective medical evidence. Imaging scans, ER records, and operative notes differentiate a viable claim from one that will be dismissed. Courts require proof that the injury directly links to Trulicity use rather than alternative causes such as alcohol consumption, elevated triglycerides, or unrelated gallstone disease. Consequently, each case succeeds or fails based on the strength of its evidence.

Injuries Alleged in Trulicity Lawsuits (Qualifying Harms)

The claims being filed against Eli Lilly focus on serious complications and catastrophic injuries, not the mild gastrointestinal upset already disclosed on the label. Patients who allege injury commonly describe:

• Acute pancreatitis: Severe abdominal pain, vomiting, elevated lipase/amylase levels, and imaging confirmation. These cases often require hospitalization, IV fluids, and in some situations, ICU care.
• Gallbladder disease: Gallstones and cholecystitis requiring cholecystectomy, followed by long-term digestive complications.
• Severe gastrointestinal events: Bowel obstruction or ileus confirmed by CT imaging or exploratory surgery, often linked to intractable vomiting and dehydration.
• Potential thyroid C-cell tumor risk: The boxed warning on Trulicity stems from rodent data, but lawsuits argue that Eli Lilly downplayed the human risk.

These are not temporary setbacks. They are injuries that can permanently alter a person’s health, finances, and quality of life. At Boesen Law, we frame these cases as catastrophic harm requiring both economic recovery for medical bills and lost income, and non-economic recovery for the trauma endured.

Who May Qualify to File a Trulicity Lawsuit

Not every adverse effect from Trulicity creates a viable lawsuit. Courts are prioritizing the most severe and well-documented cases. This includes cases where patients face permanent medical consequences and measurable financial losses. People who may qualify include:

• Patients with proven Trulicity prescriptions followed by medically confirmed acute pancreatitis, gallbladder disease, or bowel obstruction/ileus, supported by imaging, lab results, or surgical notes
• Individuals whose complications required ICU admission, emergency surgery (such as a cholecystectomy or ERCP), or prolonged hospitalizations
• Victims left with ongoing limitations, including nutritional deficiencies, chronic digestive dysfunction, or long-term pain and disability

Eligibility depends on objective evidence, and early legal review can make the difference between a claim that moves forward and one insurers dismiss as speculative.

What Compensation Could Be Recovered

When Trulicity injuries are substantiated, recovery often extends well beyond short-term hospital bills. Plaintiffs may pursue:

• Medical expenses, including ER care, diagnostic scans, lab testing, surgery, hospitalization, and long-term GI follow-up
• Lost wages and diminished earning capacity, especially for patients unable to return to their previous work roles
• Non-economic damages, such as pain, suffering, emotional distress, and reduced quality of life
• Punitive damages, if evidence shows Eli Lilly ignored or minimized known safety risks

Schedule a Free Consultation With a Trulicity Injury Attorney

Boesen Law conducts detailed case evaluations to determine eligibility, explain potential compensation, and build the strategy most likely to succeed. We provide free consultations and work on a contingency-fee basis. You do not pay unless we recover damages on your behalf. If you believe Trulicity caused your injury, reach out through our consultation page to start pursuing accountability and financial relief.

Frequently Asked Questions About Trulicity Injury Lawsuits

What symptoms suggest pancreatitis or gallbladder complications?

Severe upper-abdominal pain, vomiting, fever, or jaundice often point to pancreatitis or gallbladder disease. ER evaluation with labs and imaging is critical.

Can I have a case without surgery?

Yes. Hospitalization, confirmed diagnostics, and medical expert opinions may still establish causation and damages.

Does a thyroid warning on the label block my claim?

Not necessarily. Most lawsuits focus on pancreatitis, gallbladder disease, or ileus, arguing that these risks were not sufficiently disclosed or updated.

How long do I have to file?

Filing deadlines vary by state, but many range between two and three years from when the injury was discovered. Acting quickly is essential.

Does it matter if I used Trulicity with other GLP-1 drugs?

Yes. Lawyers need a complete medication history to establish timing, interactions, and causation in complex drug-injury cases.

Call (303) 999-9999 or complete a Free Case Evaluation form